Editas Medicine
Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases.
Leadership
David Liu
Founder (not involved anymore)
Feng Zhang
Founder (not involved anymore)
James Mullen
CEO
Jennifer Doudna
Founder (not involved anymore)
Financial Performance
Funding
Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2013
43M USD
Series A
2015
120.0 / 120.0M USD
120M USD
Series B
2016
94.40M USD
Post-IPO Equity
2020
215.6M USD
Post-IPO Equity
2021
231M USD
Post-IPO Equity
Known Investors
Name
Type
HQ
Other Relevant Investments
Corporation
United States
Private Equity
United States
Venture Capital
United States
Investment Bank
United States
Venture Capital
United States
Venture Capital
United States
Investment Bank
United States
Venture Capital
United States
Corporate Venture
United States
Asset Management
United States
Corporation
United States
Venture Capital
United States
Venture Capital
United States
Venture Capital
United States
Investment Bank
United States
Venture Capital
United States
Investment Bank
United States
*More data available at: [CB Insights] [CrunchBase] [PitchBook]
Related
News
News